⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38742 | 0.67 | — | — | |
| Ethylene SCHEMBL6271130 | 0.62 | — | — | |
| Iodide SCHEMBL5307298 | 0.62 | — | — | |
| Hydrochloric Acid SCHEMBL2073823 | 0.62 | — | — | |
| SCHEMBL1029 | 0.61 | — | — | |
| SCHEMBL70656 | 0.55 | — | — | |
| SCHEMBL821396 | 0.55 | — | — | |
| SCHEMBL6053895 | 0.55 | — | — | |
| SCHEMBL10037908 | 0.55 | — | — | |
| SCHEMBL639659 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | claimed |
| WO-2006027099-A2 | ENZYME CONJUGATES WITH A PROGRAMMABLE SPECIFICITY, WHICH REACT IN A HIGHLY SPECIFIC MANNER WITH DNA | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2006-03-16 | — | — | WO | claimed |
| EP-1015469-B1 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2005-04-13 | — | — | EP | claimed |
| US-6020315-A | Preparation having increased in vivo tolerability | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-01 | — | — | US | claimed |
| CN-113015802-B | Modulators of PNPLA expression | IONIS制药公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117980481-A | Polynucleotide compositions and methods for modulation of gene expression | 阿普塔生物公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117957022-A | Antisense compounds and methods for targeting CUG repeats | 安卓达治疗股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-106701758-B | Modulation of HSP47 expression | 日东电工株式会社 | 2020-02-07 | — | — | CN | disclosed |
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8080644-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-12-20 | — | — | US | disclosed |
| WO-1999061664-A1 | QUANTITATIVE METHOD FOR DETECTING NUCLEOTIDE CONCENTRATION | LORNE PARK RESEARCH, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999061663-A1 | DYNAMIC HYBRIDIZATION SYSTEM | LORNE PARK RESEARCH, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999061665-A2 | SOLUTION HYBRIDIZATION OF NUCLEIC ACIDS WITH ANTISENSE PROBES HAVING MODIFIED BACKBONES | LORNE PARK RESEARCH, INC. (CA) | 1999-12-02 | — | — | WO | disclosed |
| US-5955100-A | TREATMENT OF MALIGNANT TUMORS, INFLAMMATORY DISEASES, OR AUTOIMMUNE DISEASES | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1999-09-21 | — | — | US | disclosed |
| WO-1999014226-A2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 1999-03-25 | — | — | WO | disclosed |
| US-5846729-A | Assaying nucleotides in solution using a fluorescent intensity quenching effect | LORNE PARK RESEARCH, INC. (CA) | 1998-12-08 | — | — | US | disclosed |
| EP-0879605-A2 | GLYCOSYL PRODRUG CONJUGATE WITH ENHANCED TOLERANCE | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-11-25 | — | — | EP | disclosed |
| EP-0595133-A2 | Prodrugs, their preparation and use as medicaments | BEHRINGWERKE Aktiengesellschaft (DE) | 1994-05-04 | — | — | EP | disclosed |